To include your compound in the COVID-19 Resource Center, submit it here.

Gemphire reports Phase IIb data of gemcabene for hypercholesterolemia

Gemphire Therapeutics Inc. (NASDAQ:GEMP) reported top-line data from the Phase IIb ROYAL-1 trial in 105 patients with hypercholesterolemia showing that once-daily 600 mg oral gemcabene (CI-1027) met the primary endpoint of reducing mean LDL-C from

Read the full 357 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE